Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Routine Gene Testing Advised To Guide Colorectal Cancer Treatment

This article was originally published in The Gray Sheet

Executive Summary

The American Society of Clinical Oncology Jan. 13 recommended that physicians treating metastatic colorectal cancer patients who are candidates for drugs such as ImClone's Erbitux (cetuximab) or Amgen's Vectibix (panitumumab) first be tested for KRASgene mutations

You may also be interested in...

Lab Group Makes Economic Case For Gene Testing Industry

The laboratory industry, facing policy pressures, commissioned a study by Battelle Memorial Institute that finds that genetic testing is adding thousands of jobs and $16.5 billion annually to the U.S. economy.

DxS Plans PMA For Companion Test To Amgen Colorectal Cancer Drug

Personalized medicine company DxS is preparing a PMA application for a companion diagnostic to Amgen's colorectal cancer drug Vectibix, supported by clinical utility data from a recent Amgen-sponsored clinical trial, according to DxS CEO Stephen Little

Stakeholders Gather To Discuss Pandemic Response And Next Steps

As Europe’s health emergency body HERA approaches its first anniversary, an unprecedented range of stakeholders including industry bodies will be meeting in December to discuss HERA’s achievements, while a separate event will showcase the next generation of vaccines for COVID-19 and other infections.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts